Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeTACT-Africa: Triple ACTs vs ACTs for Malaria
NCT03923725Phase 3Completed
- Sponsor
- University of Oxford
- Start
- Sep 2020
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of amodiaquine and piperaquine in Plasmodium falciparum malaria (4 arms), sponsored by University of Oxford. Primary endpoint: Adequate Clinical and Parasitological Response (PCR corrected) at 42 days. Started Sep 2020; status: completed.
02
Drugs
amodiaquinepiperaquine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT03923725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03923725.